Overview Financials News + Filings Key Docs Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Employment agrmnt Quarterly results Acq. announced
|
SomaLogic, Inc.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/04/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
10/04/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
10/04/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
10/04/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
10/04/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
10/04/2023 |
8-K
| Acquisition/merger/asset purchase announced
Docs:
|
"AGREEMENT AND PLAN OF MERGER among SOMALOGIC, INC., STANDARD BIOTOOLS INC., and MARTIS MERGER SUB, INC.",
"Key Employee Severance Plan Amended and Restated Participation Notice",
"Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools",
"Legal Information Forward-looking statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, although not all forward-looking statements contain these identifying words. Readers should not place undue reliance on these forward-looking statements. Forward-looking statements may include statements regarding the expected timing of the closing of the merger; the ability of the parties to complete the merger considering the various closing conditions; the expected benefits of the merger, including estima...",
"Schedule A Schedule B Schedule C",
"Schedule A",
"VOTING AGREEMENT This Voting Agreement , dated as of October 4, 2023, is by and among SomaLogic, Inc., a Delaware corporation , Standard BioTools Inc., a Delaware corporation , Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent , and the persons listed on the attached Schedule A who are signatories to this Agreement . RECITALS WHEREAS, concurrently herewith, the Company, Parent and Merger Sub are entering into an Agreement and Plan of Merger ; WHEREAS, as of the date of this Agreement, each Stockholder is the record and/or “beneficial owner” of the approximate number of shares of Company Common Stock set forth on Schedule A opposite such Stockholder’ s name , such Stockholder’ s “ Covered Shares ”); WHEREAS, as a condition and inducement to the willingn..." |
|
08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/14/2023 |
8-K
| Quarterly results
Docs:
|
"SomaLogic, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss Unaudited Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenue Assay services revenue $ 16,597 $ 10,931 $ 35,016 $ 29,731 Product revenue 2,909 714 4,095 1,167 Collaboration revenue 762 762 1,525 1,525 Other revenue 200 1,737 211 4,701 Total revenue 20,468 14,144 40,847 37,124 Operating expenses Cost of assay services revenue 9,677 6,571 21,359 17,951 Cost of product revenue 1,498 506 2,132 778 Research and development 10,815 17,636 24,882 31,436 Selling, general and administrative 29,573 36,812 63,762 67,627 Total operating expenses 51,563 61,525 112,135 117,792 Loss from operations Other income Interest income and other, net 5,798 838 10,723 1,047 Change in fair value of ..." |
|
06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
06/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
05/11/2023 |
8-K
| Quarterly results |
05/03/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
05/02/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/25/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/21/2023 |
8-K/A
| Quarterly results |
04/14/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
04/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
03/28/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
03/28/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
03/28/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
03/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
03/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/28/2023 |
8-K
| Quarterly results |
03/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
03/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
02/14/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/03/2023 |
SC 13G
| BlackRock Inc. reports a 5.5% stake in SomaLogic, Inc. |
01/10/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data
Docs:
|
"CERTAIN INFORMATION IDENTIFIED WITH THE MARK “”, “” AND “” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. Amendment #2 to Master Collaboration Agreement Reference is hereby made to the Master Collaboration Agreement , dated September 20, 2019, by and between SomaLogic Operating Co., Inc. and Novartis Pharma AG , as amended by the First Amendment, dated June 15, 2021. This Amendment #2 to Master Collaboration Agreement , dated January 4, 2023 ) amends the Agreement as set forth herein. 1. Section 1.2.2 . Section 1.2.2 is amended as follows: in Subsection 1.2.2.b delete “joint” in two occurrences; delete the entire content of Subsection 1.2.2.e and replace it with “to obtain SomaLogic’ s c..." |
|
01/09/2023 |
8-K
| Quarterly results |
12/14/2022 |
SC 13D/A
| CMLS Holdings II LLC reports a 12.4% stake in SomaLogic, Inc. |
11/18/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
11/18/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
|
|
|